logo
  

Cyberonics Q4 Earnings Fall On Sorin Merger

Cyberonics, Inc. (CYBX) Thursday announced a sharp decline in fourth quarter net income to $10.514 million from $18.428 million last year. Earnings per share were down at $.40, compared to $0.68 a year ago. The result included one time expenses of $7.967 million on pending merger with Sorin S.p.A, expected to close by the end of September 2015.

On average, 7 analysts polled by Thomson Reuters were looking for $0.63 per share. Analysts figures usually exclude special items.

Net sales for the thirteen week period was slightly declined to $74.071 million from $74.849 million in the previous year. Wall Street was looking for $77.44 million.

The company said it will not be providing revenue or operating income guidance for fiscal 2016.

Further, the company named Jason Richey, vice president and general manager International for all U.S. commercial activity and Mark Verratti as vice president for Worldwide Sales to replace Jason. Sherrie Perkins, vice president, new business development will be the project manager for integration team. John Murphy is the new vice president for Research and development.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
French drug major Sanofi reported Thursday weak profit in its first quarter, despite higher net sales. The company also maintained its fiscal 2024 outlook. Sanofi shares were gaining around 4 percent in Paris trading as well as in pre-market activity on the Nasdaq. While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
Follow RTT